From the *Division of Cardiac Surgery, Department of Surgery, Wexner Medical Center, Columbus, Ohio
†Division of Cardiology, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Submitted for consideration September 2021; accepted for publication in revised form April 2022.
Disclosure: A.M.G. was a consultant for Abbvie Pharmaceuticals, N.A.M. Mokadam is a consultant and investigator for Abbott, Medtronic, Xylocor, Carmat, and SynCardia.; S.E. is a consultant for AbioMed and SynCardia; B.A.W. is a consultant for Abbott Laboratories and serves on the Clinical Events Committee of TransMedics OCS.
This study was supported by divisional funds.
A.M.G. and D.Z.B-M. contributed equally to this work.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML and PDF versions of this article on the journal’s Web site (www.asaiojournal.com).
Correspondence: Asvin M. Ganapathi, Division of Cardiac Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Doan Hall N809/410 West 10th Avenue, Columbus, OH 43210. Email: [email protected]; Twitter: @OSUSurgery.
